Clinical trials, why NZ needs to play catch-up

Cancer experts are warning New Zealand could be putting itself at a ten year disadvantage with leading edge cancer treatment, unless it ups its involvement in clinical trials. Cancer specialists say the rate at which genomics medicine is advancing means not actively taking part, and letting other countries do the running, could put patients here at risk. Nine to Noon speaks to Professor Michael Findlay, the head of the Discipline of Oncology at the University of Auckland's School of Medical Sciences and Chris Jackson, the clinical director of the Cancer Society of New Zealand